In re Wako Pure Chemical Industries Ltd.

4 F. App'x 853
CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 1, 2001
DocketNo. 00-1139
StatusPublished

This text of 4 F. App'x 853 (In re Wako Pure Chemical Industries Ltd.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Wako Pure Chemical Industries Ltd., 4 F. App'x 853 (Fed. Cir. 2001).

Opinion

DECISION

SCHALL, Circuit Judge.

This is an appeal from a decision of the Board of Patent Appeals and Interferences (“Board”) of the U.S. Patent and Trademark Office (“PTO”). The appeal arises out of the reexamination of U.S. Patent No. 5,216,135 issued to Urano et al. (“Ur[854]*854ano patent”). In the reexamination, the Board sustained the examiner’s rejection of claims 1 and 4-6 under 35 U.S.C. §§ 102(e) and 103(a) over U.S. Patent No. 5,338,641, issued to Pawlowski et al. (“Pawlowski patent”). Wako Chemical Industries, Ltd. (‘Wako”) is the assignee of the Urano patent. On appeal, it concedes that the Pawlowski patent discloses the subject matter of the claims at issue. However, Wako argues that the claims at issue are not anticipated by the Pawlowski patent because, according to Wako, the claims are entitled to a priority date from Urano’s earlier Japanese patent application, JP 2-019614, under 35 U.S.C. § 119. The Board rejected this contention, determining that Wako is not entitled to the priority date of the foreign application because the application lacks sufficient written description of the invention to satisfy the requirements of 35 U.S.C. § 112, H 1. We affirm.

DISCUSSION

I.

The first paragraph of 35 U.S.C. § 112 states: “The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” 35 U.S.C. § 112, 111 (1994). In a written description case, the “primary consideration is factual and depends on the nature of the invention and the amount of knowledge imparted to those skilled in the art by the disclosure.” Union Oil Co. of Cal. v. Atlantic Richfield Co., 208 F.3d 989, 996, 54 USPQ2d 1224, 1232 (Fed.Cir.2000) (quoting In re Wertheim, 541 F.2d 257, 262, 191 USPQ 90, 96 (CCPA 1976)). An analysis of the adequacy of a disclosure begins with a direct comparison of the claims to the disclosure in the priority document. If the claim language is not expressly supported by the disclosure, then the language of the priority document must be analyzed for what it conveys to one skilled in the art. Ralston Purina v. Far-Mar-Co ., Inc., 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed.Cir.1985). The written description requirement does not dictate that the applicant describe the invention exactly. Rather, what is required is that, as of the filing date, the inventor convey with reasonable clarity to those skilled im the art that the inventor was in possession of the subject matter claimed. See Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed.Cir.1991). We review the Board’s decision on whether the disclosure of the Japanese patent application has a written description that supports claims 1 and 4-6 of the Urano patent for substantial evidence. See Dickinson v. Zurko, 527 U.S. 150, 152, 119 S.Ct. 1816, 144 L.Ed.2d 143 (1999); In re Gartside, 203 F.3d 1305, 1313, 53 USPQ2d 1769, 1773-74 (Fed.Cir.2000).

II.

The Urano patent is directed to compounds for use in manufacturing semiconductor devices. The patent claims diazodisulfone compounds that are useful as photosensitive material that generates acid upon irradiation. Claim ;1 of the Urano patent reads: “A diazodisulfone compound of the formula:

R^OüCSOaR2 II N2

wherein R1 is a branched or cyclic alkyl group having 3 to 8 carbon atoms; and R2 is a straight-chained, branched or cyclic alkyl group having 1 to 8 carbon atoms.” Urano Patent, col. 14, II. ;31 — 39. Claim 4 [855]*855of the Urano patent similarly recites: “A diazodisulfone compound of the formula

R^OaCSOaR2 II N2

wherein R1 is a branched or cyclic alkyl group having 3 to 8 carbon atoms; and R2 is a branched or cyclic alkyl group having 3 to 8 carbon atoms.” Id. at col. 14, II. 60-68. Both claims are based on the same chemical structure, wherein R1 and R2 represent variables, moieties that change in accordance with the specific parameters of the claim language. For example, the compound of claim 1 can be any compound wherein R1 is a branched or cyclic chain of carbon atoms that has anywhere between 3 and 8 carbon atoms in the chain. Claims 5 and 6 depend from claim 4. Id. at col. 15, 1.1 — col. 16,1. 5.

The Japanese patent application discloses compounds based on the exact same chemical structure, but describes R1 and R2 differently. R1 and R2 are described in the application as being independently chosen from one of seven categories: 1) Cuo straight-chain, branched or cyclic alkyl group; 2) CH0 haloalkyl group; 3) Ca-io alkenyl group; 4) Ca_i0 phenyl group; 5) Ca_io substituted phenyl group (with substitutional group of halogen atom, C140 straight-chain, branched or cyclic alkyl group, Ci_10 straight-chain or branched alkoxy group, C^o haloalkyl group, nitro group, nitrile group or amido group); 6) Ca_10 aralkyl group; or 7) Ca_i0 substituted aralkyl group (with substitutional group of halogen atom, C140 straight-chain, branched or cyclic alkyl group, C140 straight-chain or branched alkoxy group, Cuo haloalkyl group, nitro group, nitrile group or amido group).

Only the first of the above categories is at issue in this case. The language of that category indicates that the invention of the Japanese application is a compound wherein R1 and R2 are moieties that contain anywhere from one to ten single-bonded carbon atoms in a chain. While the Urano patent claims the same basic structure of the diazodisulfone, in contrast to the Japanese application, it does not describe R1 and R2 as being selected specifically from category one, the Cuo straight-chain, branched or cyclic alkyl group. Rather, claims 1 and 4 of the Urano patent each claim only a subset of this category. In the Japanese application, R1 and R2 are 1-10 carbons long. In claim 1 of the Urano patent, R1 is 3-8 carbons long and R2 is 1-8 carbons long. Additionally, R1 in the Urano patent cannot be a straight carbon chain; it must be branched or cyclic. Similarly, in claim 4 of the Urano patent, neither R1 nor R2 can be straight-chained, and both are limited to 3-8 carbons out of the possible ten described in the Japanese application.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dickinson v. Zurko
527 U.S. 150 (Supreme Court, 1999)
Ralston Purina Company v. Far-Mar-Co, Inc.
772 F.2d 1570 (Federal Circuit, 1985)
In Re Robert J. Gartside and Richard C. Norton
203 F.3d 1305 (Federal Circuit, 2000)
In re Wertheim
541 F.2d 257 (Customs and Patent Appeals, 1976)
In re Driscoll
562 F.2d 1245 (Customs and Patent Appeals, 1977)
Dickinson v. Zurko
527 U.S. 150 (Supreme Court, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
4 F. App'x 853, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-wako-pure-chemical-industries-ltd-cafc-2001.